Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Pain associated with neoplasms may be of somatic, visceral, or neuropathic origin.Visceral pain or pain that is mediated by the sympathetic fibers in the perineal area associated with malignancy in the pelvis may be effectively treated with neurolysis of impar ganglion.In recent years, radiofrequency lesioning of the ganglion Impar has evolved as a novel non pharmacological technique for the management of patients suffering from intractable perineal pain.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Conventional radiofrequency | Active Comparator | In this group we will use conventional radiofrequency thermocoagulation in the management of perineal cancer pain |
|
| Cooled radiofrequency | Active Comparator | In this group we will use cooled radiofrequency in the management of perineal cancer pain |
|
| Neurolytic block of Ganglion | Active Comparator | In this group we will use neurolysis of ganglion impar in the management of perineal cancer pain |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| cooled radiofrequency , | Device | In Cooled RF, after placement of the introducer needle, the 18 gauge internally cooled RF electrode is used for 90 seconds at a temperature of 60°C. |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients gaining ≥ 50% reduction of their pre procedural pain at VAS Score from baseline value. | Patients rate pain on a scale from 0-10, 0 being no pain and 10 being the worst pain imaginable. | 2 hours, 24 hours,1 week, 2 weeks, 1 month, 3 months. |
| Measure | Description | Time Frame |
|---|---|---|
| Total Tramadol consumption | we will measure consumption of tramadol either it increasing or decreasing . | at 2 weeks, 1 month, 2 months and 3 months' post procedural. |
| Measure | Description | Time Frame |
|---|---|---|
| Patient's satisfaction by the Global Perceived Effect questionnaire | provides patient feedback on your empathy and relationship-building skills during consultations. | at baseline, 2 weeks, 1 month, 3 months. |
Inclusion Criteria:
Exclusion Criteria:
Infection of the skin at or near site of needle puncture.
Coagulopathy or prolonged bleeding time.
Drug hypersensitivity or allergy to the studied drugs.
Central or peripheral neuropathy .
Significant organ dysfunction as respiratory , liver or renal failure.
Any psychiatric illness that would interfere with the perception and the assessment of pain.
Vertebral anomalies.
-
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| aya ali | Contact | 01068744428 | totaaboeldahab8@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| aya ali | Assiut University | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| D012004 | Rectal Neoplasms |
| D014846 | Vulvar Neoplasms |
| D014625 | Vaginal Neoplasms |
| ID | Term |
|---|---|
| D015179 | Colorectal Neoplasms |
| D007414 | Intestinal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| conventional radiofrequency | Device | In conventional RF group lesion will be performed at 80°C for 120 seconds. |
|
| neurolysis of ganglion | Device | In neurolytic block, Once the position of the needle tip confirmed, 4 - 6 mL of 8% phenol in saline will be injected followed by 1 mL of saline to avoid the deposition of phenol within the intervertebral disc material. |
|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D007410 | Intestinal Diseases |
| D012002 | Rectal Diseases |
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D014845 | Vulvar Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
| D014623 | Vaginal Diseases |